Bispecific reagents for aids therapy

Details Bispecific reagents for aids therapy Bispecific reagents for aids therapy

C - Chemistry, Metallurgy

12

P

C12P 21/08 (2006.01) A61K 39/42 (2006.01) A61K 47/48 (2006.01) C07K 14/16 (2006.01) C07K 14/73 (2006.01) C07K 16/10 (2006.01) C07K 16/28 (2006.01) C07K 16/46 (2006.01) C12N 5/06 (2006.01) A61K 38/00 (2006.01)

Patent

CA 2062795

2062795 9100360 PCTABS00003 Bispecific molecules which react both with the high-affinity Fc.gamma. receptor of human effector cells and with a virus or virus component are disclosed. Binding of the molecules to the Fc receptors found on effector cells is not blocked by human immunoglobulin G. The molecules are useful for targeting human effector cells (e.g. macrophages) against a viral target (e.g. HIV or HIV-infected cell). For this purpose, bispecific molecules can be constructed containing the binding region derived from an anti-Fc.gamma. receptor antibody and the CD4 molecule or CD4 binding domain of the envelope glycoprotein gp120 of HIV. Alternatively, bispecific antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a HIV-specific antibody such as anti-gp120 antibody. Targeted effector cells can be used to kill virus by cell mediated antibody dependent cytolysis.

Affiliated with

Also associated with

Rating

Bispecific reagents for aids therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bispecific reagents for aids therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bispecific reagents for aids therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1521988